Moa Life Plus

Moa Life Plus FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Moa Life Plus (142760.KQ) as of Oct 30, 2026 is 47.38 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 22.24 % — a change of 113.03% (higher).

FCF Conversion

47.38 %

YoY

113.03%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Moa Life Plus is 2025 47.38 % . FCF Conversion Rate (FCF/EBITDA) of Moa Life Plus was 2024 22.24 % . It decreases by 113.03% higher compared to the previous year.

The Moa Life Plus FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
74.48 KRW
Jan 1, 2019
91.63 KRW
Jan 1, 2020
109.79 KRW
Jan 1, 2021
34.41 KRW
Jan 1, 2022
96.46 KRW
Jan 1, 2023
72.37 KRW
Jan 1, 2024
22.24 KRW
Jan 1, 2025
47.38 KRW
The Moa Life Plus FCF Conversion history
YEARFCF ConversionYoY
47.38 %+113.03%
22.24 %-69.27%
72.37 %-24.97%
96.46 %+180.30%
34.41 %-68.66%
109.79 %+19.83%
91.63 %+23.03%
74.48 %-55.46%
167.21 %+7.94%
154.92 %+454.97%
27.91 %-54.31%
61.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Moa Life Plus Stock analysis

What does Moa Life Plus do? BL Corp. develops biopharmaceutical products and manufactures health functional foods and functional cosmetics. The company distributes Glu 100 Tablets, CellribonQ, and GentaQ to general hospitals and pharmacies. It generates revenue through the sale of these pharmaceuticals and health-related products to healthcare providers and retail outlets. The firm's product portfolio includes Glu 100 Tablets, CellribonQ, and GentaQ, which are distributed to general hospitals and pharmacies. These products are sold as part of the company's pharmaceutical and medical supplies distribution business. Revenue is derived from the sale of these branded medicines and health functional products. BL Corp. focuses on the distribution of specific branded pharmaceuticals and health functional products. The company's primary customers are general hospitals and pharmacies, which purchase Glu 100 Tablets, CellribonQ, and GentaQ for resale or direct use in healthcare settings. Moa Life Plus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moa Life Plus stock

FCF Conversion Rate (FCF/EBITDA) of Moa Life Plus is 47.38 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Moa Life Plus changed from 22.24 % to 47.38 %, representing a 113.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Moa Life Plus since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Moa Life Plus with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Moa Life Plus

All Key Metrics — Moa Life Plus